States / Tennessee / SB 436

SB 436 In Committee

Drugs, Prescription - As enacted, adds mandating the use of biosimilar drugs as a cost-saving measure the bureau of TennCare may implement; adds that a health carrier, health benefit plan, or utilization review organization may require a patient to try a biosimilar product prior to providing coverage for the equivalent branded prescription drug; requires the TennCare pharmacy advisory committee to consider as a factor the use of biosimilar drugs in the committee's recommendation to the bureau of TennCare on any drugs to be added to the state preferred drug list. - Amends TCA Title 4; Title 53; Title 56; Title 68 and Title 71.

Introduced
In Committee
Floor
Crossed Over
Passed
Enacted

No summary has been published for this bill. The full text is on the Bill text tab.

Chamber
Senate
Introduced
Jan 28, 2025
Last action
Apr 28, 2025 — Comp. became Pub. Ch. 206
Session
114
Momentum
31 · Low